January 28, 2016

June 9, 2015

The SEC charged three men living in California with insider trading in the stock and options of a biotechnology company where one of them worked.  Specifically, the SEC alleges Michael J. Fefferman learned material nonpublic information as senior director of information technology at Ardea Biosciences Inc. and tipped off his brother-in-law in advance of major public announcements related to two pharmaceutical trials, a licensing agreement for a cancer drug, and eventually the acquisition of the company by AstraZeneca PLC.  SEC

*     *     *

If you would like more information or would like to speak to a member of Constantine Cannon’s whistleblower lawyer team, please click here.